banner2

Getting started
Tetrabutylammonium Difluorotriphenylsilicate CAS 163931-61-1

Tetrabutylammonium Difluorotriphenylsilicate CAS 163931-61-1 - China Manufacturers, Suppliers, Factory

Tetrabutylammonium Difluorotriphenylsilicate CAS 163931-61-1, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

Tetrabutylammonium Difluorotriphenylsilicate TBAT CAS 163931-61-1 Purity 97.0 (NonaqueousTitration) Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — TBAT CAS 163931-61-1 Purity >97.0% (NonaqueousTitration)
Read More

Tetrabutylammonium Chloride Hydrate CAS 37451-68-6 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Tetrabutylammonium Chloride Hydrate CAS 37451-68-6 Purity ≥98.0%

Trimagnesium Dicitrate Nonahydrate CAS 153531-96-5 Magnesium (Mg) 14.5%~16.4%

Saccharin Insoluble CAS 81-07-2 Purity >99.0% (HPLC)

2,3-Butanedione CAS 431-03-8 Purity >99.0% (GC)

Citric Acid Anhydrous CAS 77-92-9 Assay 99.5~100.5%

Dimethyl Dicarbonate (DMPC) CAS 4525-33-1 Purity ≥99.8% (HPLC) Food Additive Preservative

banner1

Top Selling Products

Related Blog
Reviews

Paxlovid: what we know about Pfizer's Covid-19 pill

Pfizer is seeking emergency use authorisation from the FDA for its novel Covid-19 antiviral pill Paxlovid. Share Article On the heels of Merck antiviral molnupiravir’s UK approval, Pfizer...
The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021

The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021 As the world’s second largest medical market, ...
The Nobel Prize in Chemistry 2021 Benjamin List and David W.C. MacMillan

6 October 2021 The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2021 to Benjamin List Max-Planck-Institut für Kohlenforschung, Mülheim an der Ruhr, Germany Da...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) -Shanghai Ruifu Chemical Co., Ltd. will attend with customers.

Shanghai Ruifu Chemical Co., Ltd. will attend the The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) with customers. The 87th China International ...
Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models This forum focuses on the interdisciplinary and cutting-edge technologies...

2022.10.07 13:03:06
2022.08.05 23:10:19
2022.07.01 04:24:52
2022.03.24 04:34:37
2022.03.03 18:37:54
2022.02.22 10:47:28

related search